Clinical Trial Update: Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ex vivo-expanded regulatory T cells plus low-dose interleukin-2 for steroid-refractory chronic graft-versus-host disease; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Regulatory T cell therapy (regulatory T cells)

Snippet

Sponsor: Leslie Kean | Conditions: Graft Versus Host Disease (cGvHD) | Phase 1 | Status: NOT_YET_RECRUITING